Dr. Hugh James Freeman, MD, FRCPC, FACP, Department of Gastroenterology, University of British Columbia, Hospital, 2211 Wesbrook Mall, Vancouver, BC V6T 1W5, Canada. hugfree@shaw.ca
Article-Type of This Article
Observer
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Hugh James Freeman, Department of Medicine (Gastroenterology), University of British Columbia, Vancouver, BC, Canada
ORCID number: $[AuthorORCIDs]
Correspondence to: Dr. Hugh James Freeman, MD, FRCPC, FACP, Department of Gastroenterology, University of British Columbia, Hospital, 2211 Wesbrook Mall, Vancouver, BC V6T 1W5, Canada. hugfree@shaw.ca
Telephone: +1-604-8227216
Fax: +1-604-8227236
Received: December 1, 2007 Revised: January 3, 2008 Published online: February 28, 2008
Abstract
Recent reports have suggested that autoimmune enteropathy involving the small bowel may occur in adults as well as in children. Apparently, the endoscopic and histological changes are similar to celiac disease before treatment, but these are not altered by any form of dietary restriction, including a gluten-free diet. As in celiac disease, histologic changes in gastric and colonic biopsies have also been recorded. Anti-enterocyte antibodies detected with immunofluorescent methods have been reported by a few laboratories, but these antibodies appear not to be specific and may simply represent epiphenomena. A widely available, reproducible and quantitative anti-enterocyte antibody assay is needed that could be applied in small bowel disorders that have the histological appearance of celiac disease, but fail to respond to a gluten-free diet.
A number of reports in adults[1–7], similar to prior publications in children[8–10], have described an entity, termed autoimmune enteropathy (AIE), that appears to involve mainly, but not exclusively, the small intestine[47]. Some of the histologic changes, at least in adults, have been reported to permit pathological distinction from other disorders characterized by severe small bowel mucosal architectural abnormalities, specifically untreated celiac disease (Table 1). Specifically, reduced numbers of intraepithelial lymphocytes, especially in surface epithelium, may be evident in AIE compared to adult celiac disease[7]. In AIE, the diarrhea fails to respond to any form of dietary restriction, including a gluten-free diet[8]. Circulating anti-enterocyte and/or anti-goblet cell antibodies are generally present in diagnosed AIE[7], but their precise significance in the pathogenesis of this disorder is not clear. It has been postulated elsewhere that these antibodies likely only represent epiphenomena since these appear after the onset of mucosal damage and then disappear following treatment, but before return to normal mucosa[11]. In some, pathological changes in gastric and colonic biopsies have also been recorded[7].
Table 1 Comparison of celiac disease and autoimmune enteropathy in adults.
Celiac disease
Autoimmune enteropathy
Diarrhea
Responds to gluten-free diet
No response to diet therapy
Endoscopic and microscopic changes
Not specific, responds to gluten-free diet
Not specific, similar to celiac disease (pre-gluten-free diet)
Gastric and colon microscopic changes
May be abnormal
May be abnormal
Ages reported
All ages
All ages, mainly children
Autoimmune phenomena
Present
Present
TTG antibodies
Usually present
Present in 30% or more
Prognosis
Good with gluten-free diet
Unknown, anecdotal results
The antibodies are reported to appear as a linear pattern along the apex or brush border of the enterocytes, sometimes with an extension along the baso-lateral membrane[10]. Usually, the antibodies are IgG in type, sometimes complement-fixing, while in some, IgM and IgA antibodies occur[710]. These anti-enterocyte antibodies do not appear in celiac disease, Crohn’s disease or ulcerative colitis[10]. Antibodies may also react with mucus in goblet cells, but these seem to be even less specific than anti-enterocyte antibodies[10]. For example, antibodies to goblet cells have been detected in chronic inflammatory bowel disease patients and their first-degree relatives[12].
Other co-existent autoimmune disorders as well as antibodies of different types have been observed in AIE. Indeed, even antibodies to tissue transglutaminase (tTG) have been described in over 30% of the largest series of reported AIE patients[7]. However, the presence of an associated autoimmune disorder is not a truly distinctive or differentiating clinical feature as autoimmune disorders have been commonly reported in several small bowel disorders, particularly in celiac disease, regardless of duration of gluten exposure[13–16].
DIAGNOSTIC DIFFICULTIES AND THE FUTURE
Most clinicians are likely to encounter significant difficulties in securing a definite diagnosis of AIE, because its precise differentiation from other small bowel disorders may be very difficult, at least based on current suggested criteria for diagnosis of adult AIE[7]. A number of factors have come into play. First, dietary compliance, even in an adult, may be exceedingly difficult to define. If dietary indiscretion is intentional or unavoidable, it may be very obvious. However, most experienced clinicians know that it may be very difficult to confirm that a specific diet has been continuously followed for prolonged periods (eg., gluten-free diet in celiac disease). Alternative “markers” have been suggested. For example, reduced antibodies to tTG in celiac disease have been suggested by some to provide a marker of compliance to a gluten-free diet, but others dispute this claim[17–19]. Second, failure to resolve symptoms with dietary restriction (eg., gluten) should not necessarily translate into a diagnosis of a persistent or refractory disorder. Other concomitant causes for symptoms, including functional disorders, may co-exist. Third, evidence for persistent histopathological changes in spite of dietary restriction may be more reflective of an inadequate duration of dietary restriction in order to detect a response or an inadequate method of assessment. In celiac disease, for example, histological evidence of normalization of pathological changes may require months or years, and usually occurs first in the most distal sites of involvement. Only later, sometimes much later, can a definite histopathological response to a gluten-free diet be documented in the most proximal small bowel (where endoscopic biopsies are generally taken). Fourth, only a limited number of laboratories claim to be able to detect anti-enterocyte antibodies, even though required methodology is straightforward, i.e., immunofluorescence microscopy. While anti-enterocyte antibodies are apparently not present in celiac disease[10], it appears that some of the histopathologic features of adult AIE may co-exist with those of celiac disease[7], further confusing the clinical picture.
In addition, these anti-enterocyte antibodies are not specific for AIE being reported in HIV-associated immunodeficiency syndromes without intestinal symptoms[20]. As noted earlier, anti-goblet cell antibodies which may be even less specific have been described in inflammatory bowel disease patients and their relatives[12]. Finally, and most importantly, immunofluorescent methods for serum antibody detection are very subjective, and observer-dependent. Use of immunofluorescent methods for screening (eg. anti-endomysial antibodies for celiac disease) are often based on “in-house” assays and may be difficult to reproduce between different laboratories, even if the same sources of sample material are used.
Further studies are needed to determine if AIE in adults is truly a separable clinical entity that may be amenable to other treatments. The most critical element needed is a widely available, reproducible, sensitive and specific assay for anti-enterocyte antibodies that might permit separation of AIE from other small bowel disorders and be an important addition to the investigative methods currently available for persistent diarrhea disorders in adults. To date, different therapeutic options have been used in an anecdotal fashion in adults diagnosed with AIE[7], but a conclusive approach to treatment still requires further evaluation.
Footnotes
Peer reviewer: Hitoshi Asakura, Director, Emeritus Professor,
International Medical Information Center, Shinanomachi Renga
Bldg.35, Shinanomachi, Shinjukuku, Tokyo 160-0016, Japan
Corazza GR, Andreani ML, Biagi F, Corrao G, Pretolani S, Giulianelli G, Ghironzi G, Gasbarrini G. The smaller size of the ‘coeliac iceberg’ in adults.Scand J Gastroenterol. 1997;32:917-919.
[PubMed] [DOI][Cited in This Article: ]
Mais DD, Mulhall BP, Adolphson KR, Yamamoto K. Thymoma-associated autoimmune enteropathy. A report of two cases.Am J Clin Pathol. 1999;112:810-815.
[PubMed] [DOI][Cited in This Article: ]
Daum S, Sahin E, Jansen A, Heine B, Riecken EO, Zeitz M, Schmidt W. Adult autoimmune enteropathy treated successfully with tacrolimus.Digestion. 2003;68:86-90.
[PubMed] [DOI][Cited in This Article: ]
Carroccio A, Volta U, Di Prima L, Petrolini N, Florena AM, Averna MR, Montalto G, Notarbartolo A. Autoimmune enteropathy and colitis in an adult patient.Dig Dis Sci. 2003;48:1600-1606.
[PubMed] [DOI][Cited in This Article: ]
Leon F, Olivencia P, Rodriguez-Pena R, Sanchez L, Redondo C, Alvarez I, Moreira V, Roy G. Clinical and immunological features of adult-onset generalized autoimmune gut disorder.Am J Gastroenterol. 2004;99:1563-1571.
[PubMed] [DOI][Cited in This Article: ]
Rolny P, Sigurjonsdottir HA, Remotti H, Nilsson LA, Ascher H, Tlaskalova-Hogenova H, Tuckova L. Role of immunosuppressive therapy in refractory sprue-like disease.Am J Gastroenterol. 1999;94:219-25.
[PubMed] [DOI][Cited in This Article: ]
Walker-Smith JA, Unsworth DJ, Hutchins P, Phillips AD, Holborow EJ. Autoantibodies against gut epithelium in child with small-intestinal enteropathy.Lancet. 1982;1:566-567.
[PubMed] [DOI][Cited in This Article: ]
Savage MO, Mirakian R, Wozniak ER, Jenkins HR, Malone M, Phillips AD, Milla PJ, Bottazzo GF, Harries JT. Specific autoantibodies to gut epithelium in two infants with severe protracted diarrhoea.J Pediatr Gastroenterol Nutr. 1985;4:187-195.
[PubMed] [DOI][Cited in This Article: ]
Unsworth J, Hutchins P, Mitchell J, Phillips A, Hindocha P, Holborow J, Walker-Smith J. Flat small intestinal mucosa and autoantibodies against the gut epithelium.J Pediatr Gastroenterol Nutr. 1982;1:503-513.
[PubMed] [DOI][Cited in This Article: ]
Folwaczny C, Noehl N, Tschop K, Endres SP, Heldwein W, Loeschke K, Fricke H. Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives.Gastroenterology. 1997;113:101-106.
[PubMed] [DOI][Cited in This Article: ]
Ventura A, Magazzu G, Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease.Gastroenterology. 1999;117:297-303.
[PubMed] [DOI][Cited in This Article: ]
Sategna Guidetti C, Solerio E, Scaglione N, Aimo G, Mengozzi G. Duration of gluten exposure in adult coeliac disease does not correlate with the risk for autoimmune disorders.Gut. 2001;49:502-505.
[PubMed] [DOI][Cited in This Article: ]
Viljamaa M, Kaukinen K, Huhtala H, Kyronpalo S, Rasmussen M, Collin P. Coeliac disease, autoimmune diseases and gluten exposure.Scand J Gastroenterol. 2005;40:437-443.
[PubMed] [DOI][Cited in This Article: ]
Guariso G, Conte S, Presotto F, Basso D, Brotto F, Visona Dalla Pozza L, Pedini B, Betterle C. Clinical, subclinical and potential autoimmune diseases in an Italian population of children with coeliac disease.Aliment Pharmacol Ther. 2007;26:1409-1417.
[PubMed] [DOI][Cited in This Article: ]
Bazzigaluppi E, Roggero P, Parma B, Brambillasca MF, Meroni F, Mora S, Bosi E, Barera G. Antibodies to recombinant human tissue-transglutaminase in coeliac disease: diagnostic effectiveness and decline pattern after gluten-free diet.Dig Liver Dis. 2006;38:98-102.
[PubMed] [DOI][Cited in This Article: ]
Vahedi K, Mascart F, Mary JY, Laberenne JE, Bouhnik Y, Morin MC, Ocmant A, Velly C, Colombel JF, Matuchansky C. Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease.Am J Gastroenterol. 2003;98:1079-1087.
[PubMed] [DOI][Cited in This Article: ]
Tursi A, Brandimarte G, Giorgetti GM. Lack of usefulness of anti-transglutaminase antibodies in assessing histologic recovery after gluten-free diet in celiac disease.J Clin Gastroenterol. 2003;37:387-391.
[PubMed] [DOI][Cited in This Article: ]
Martin-Villa JM, Camblor S, Costa R, Arnaiz-Villena A. Gut epithelial cell autoantibodies in AIDS pathogenesis.Lancet. 1993;342:380.
[PubMed] [DOI][Cited in This Article: ]